{"entity":{"id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ZGGS18 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06938880 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 60 participants planned, started 2025-05-20 and due to reach its primary completion in 2027-05. Interventions recorded: ZGGS18 for Injection and ZG005 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06938880","url":"https://clinicaltrials.gov/study/NCT06938880"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06938880","phase":"1/2","setting":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":60,"outcomes":[]},"route":"/trials/nct06938880/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}